NDA 215910 · Sparc
Sezaby
Phenobarbital Sodium · Intravenous
Priority reviewOrphanLast checked: Nov 19, 2026Latest source record: Nov 17, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Nov 17, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
57
15 Phase 3, 2 recruiting
FAERS reports
416
405 serious, 62 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. If a decision is made for concomitant use of these drugs, limit dosages and durations to the minimum required, and follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1) and Drug Interactions (7.3)]. Dependence and Withdrawal Reactions After Use of SEZABY for a Longer Duration than Recommended The continued use...
What it is approved for
From the label in effect Oct 23, 2026.
SEZABY is indicated for the treatment of neonatal seizures in term and preterm infants. SEZABY is a barbiturate indicated for the treatment of neonatal seizures in term and preterm infants.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- SEZABY · PHENOBARBITAL SODIUM 100MG/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Phenobarbital" as an intervention, any sponsor and status, largest first.
- Antenatal Phenobarbital to Prevent Neonatal Intracranial HemorrhagePivotal-lookingCompleted
NICHD Neonatal Research NetworkResearch network
NCT00009620 · 610 participants · Start Feb 1993 · Primary completion Feb 1995
Drug: Phenobarbital; Saline · For: Infant, Newborn; Infant, Low Birth Weight; Infant, Small for Gestational Age and 2 more
Sites: Palo Alto, California; New Haven, Connecticut; Washington D.C., District of Columbia · 11 sites in all
- Pharmacovigilance in Gerontopsychiatric PatientsPivotal-lookingTerminated
Hannover Medical SchoolAcademic, hospital or other
NCT02374567 · 407 participants · Start Jan 2015 · Primary completion Jun 28, 2017
Drug: Phenobarbital; Phenytoin and 95 more · For: Dementia; Depression; Schizophrenia and 2 more
Sites: Augsburg, Germany; Berlin, Germany; Hanover, Germany · 5 sites in all
- A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset SeizuresPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01713946 · 366 participants · Start Apr 29, 2013 · Primary completion Oct 25, 2017
Drug: RAD001; Placebo and 2 more · For: Tuberous Sclerosis Complex-associated Refractory Seizures
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 104 sites in all
- Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset SeizuresPivotal-lookingCompleted
West-Ward PharmaceuticalIndustry
NCT01284556 · 314 participants · Start Nov 2010 · Primary completion Jan 2013
Drug: Phenobarbital; Placebo tablet · For: Epilepsy
Sites: Lexington, Kentucky; Oklahoma City, Oklahoma; San Juan, Puerto Rico · 4 sites in all
- Efficacy of Intravenous Levetiracetam in Neonatal SeizuresPivotal-lookingCompleted
Richard H. HaasAcademic, hospital or other
NCT01720667 · 280 participants · Start Mar 2013 · Primary completion Oct 31, 2017
Drug: Intravenous levetiracetam; Intravenous phenobarbital · For: Neonatal Seizures
Sites: San Diego, California
- Levetiracetam Versus Phenobarbitone for the Treatment of Neonatal Seizures in a Tertiary Care Hospital.Pivotal-lookingCompleted
Hayat Abad Medical Complex, PeshawarGovernment (non-federal)
NCT07401433 · 260 participants · Start Apr 8, 2024 · Primary completion Mar 31, 2025
Drug: Levetiracetam; Phenobarbital Sodium Injection · For: Neonatal Seizures
Sites: Dera Ismāīl Khān, Pakistan
- Childhood Convulsive Status Epilepticus Management In A Resource Limited SettingPivotal-lookingCompleted
University of Cape TownAcademic, hospital or other
NCT03650270 · 198 participants · Start Mar 1, 2015 · Primary completion Mar 1, 2018
Drug: Phenobarbital · For: Pediatric Status Epilepticus
Sites: Cape Town, South Africa
- Levetiracetam Versus Phenobarbital in Benzodiazepines Unresponsive Paediatric Prolonged SeizuresPivotal-lookingRecruiting
Ministry of Health and Sports, MyanmarGovernment (non-federal)
NCT07098728 · 180 participants (planned) · Start Jul 22, 2025 · Primary completion Mar 28, 2026
Drug: Levetiracetam IV; Phenobarbital · For: Seizure
Sites: Yangon, Burma · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- seizure68
- off label use60
- drug ineffective58
- epilepsy27
- status epilepticus21
- product use in unapproved indication19
- pallor18
- sepsis18
- drug ineffective for unapproved indication17
- condition aggravated16
- confusional state15
- drug resistance15
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 5 |
| 2005 | 6 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 7 |
| 2012 | 6 |
| 2013 | 15 |
| 2014 | 10 |
| 2015 | 12 |
| 2016 | 19 |
| 2017 | 12 |
| 2018 | 50 |
| 2019 | 37 |
| 2020 | 19 |
| 2021 | 34 |
| 2022 | 37 |
| 2023 | 40 |
| 2024 | 41 |
| 2025 | 29 |
| 2026 | 30 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of seizures in the neonate: Guidelines and consensus-based recommendations-Special report from the ILAE Task Force on Neonatal Seizures.
Pressler RM, Abend NS, Auvin S, et al. · Epilepsia 2023 · Systematic Review, Meta-Analysis
- Epilepsy.
Marson AG, Maguire M, Ramaratnam S · BMJ Clin Evid 2009 · Systematic Review
- Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial.
Sharpe C, Reiner GE, Davis SL, et al. · Pediatrics 2020 · Clinical Trial, Phase II, Comparative Study
- Clinical Aspects of Palliative Sedation in Prospective Studies. A Systematic Review.
Arantzamendi M, Belar A, Payne S, et al. · J Pain Symptom Manage 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Anti-seizure medications for neonates with seizures.
Abiramalatha T, Thanigainathan S, Ramaswamy VV, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Phenobarbital for acute alcohol withdrawal: a prospective randomized double-blind placebo-controlled study.
Rosenson J, Clements C, Simon B, et al. · J Emerg Med 2013 · Randomized Controlled Trial
Sponsor: Sparc
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.